Articles Accepted

Comparative anti-inflammatory studies on Timolol Maleate and Diclofenac sodium in in vitro and In vivo models by oral routes
by Dr. Doshi Gaurav Mahesh, 17 Feb 2023
Co-Author(s): Namrata Nailwal

Aims and ideas: To achieve a therapeutic anti-inflammatory response, the drug should be able to have an inhibition effect against inflammatory and pro-inflammatory mediators along with the ability to activate the anti-inflammatory mediators. In the current study, a non-selective beta-blocker Timolol maleate was selected to screen its potential for anti-inflammatory activity. Methods: The study was conducted using in vitro assays and in vivo models of rats. Timolol was tested for its anti-inflammatory activity at three dose levels (1.028mg kg, 5.14mg/kg, and 10.28mg/kg). Furthermore, the investigation was supported by the estimation of Tumor necrosis factor-alpha, Interleukin-1 and histopathological examination. Main findings: It was observed that at, 5.14mg/kg, and 10.28mg/kg showed anti-inflammatory activities. Moreover, plasma levels of TNF-α and IL-showed inhibition. Histopathological examination confirmed the highest anti-inflammatory activity at 5.14mg/kg. Principal conclusions: Thus, the conducted studies revealed that Timolol when given orally does possess an anti-inflammatory potential.

Current Issue
Quick Contact